Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
80,797,753
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
58,230,116
-
Shares change
-
+1,560,147
-
Total reported value, excl. options
-
$1,338,678,295
-
Value change
-
+$29,100,921
-
Put/Call ratio
-
46%
-
Number of buys
-
66
-
Number of sells
-
48
-
Price
-
$22.99
Institutional Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) as of Q2 2023
As of 30 Jun 2023 Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) had 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 58,230,116 shares of stock of the company.
Largest 10 holders included Atlas Venture Life Science Advisors, LLC, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, BVF INC/IL, BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, and Redmile Group, LLC.
This table shows 150 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.